Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV
- 1 March 1995
- journal article
- Published by Springer Nature in Genetica
- Vol. 95 (1-3), 51-70
- https://doi.org/10.1007/bf01435001
Abstract
Hemophilia-AIDS has been interpreted in terms of two hypotheses: the foreign-protein-AIDS hypothesis and the Human Immunodeficiency Virus (HIV)-AIDS hypothesis. The foreign-protein-AIDS hypothesis holds that proteins contaminating commercial clotting factor VIII cause immunosuppression. The foreign-protein hypothesis, but not the HIV hypothesis, correctly predicts seven characteristics of hemophilia-AIDS: 1) The increased life span of American hemophiliacs in the two decades before 1987, although 75% became infected by HIV —because factor VIII treatment, begun in the 1960s, extended their lives and simultaneously disseminated harmless HIV. After 1987 the life span of hemophiliacs appears to have decreased again, probably because of widespread treatment with the cytotoxic anti-HIV drug AZT. 2) The distinctly low, 1.3–2%, annual AIDS risk of hemophiliacs, compared to the higher 5–6% annual risk of intravenous drug users and male homosexual aphrodisiac drug users — because transfusion of foreign proteins is less immunosuppressive than recreational drug use. 3) The age bias of hemophilia-AIDS, i.e. that the annual AIDS risk increased 2-fold for each 10-year increase in age —because immunosuppression is a function of the lifetime dose of foreign proteins received from transfusions. 4) The restriction of hemophilia-AIDS to immunodeficiency diseases — because foreign proteins cannot cause non-immunodeficiency AIDS diseases, like Kaposi's sarcoma. 5) The absence of AIDS diseases above their normal background in sexual partners of hemophiliacs — because transfusion-mediated immunotoxicity is not contagious. 6) The occurrence of immunodeficiency in HIV-free hemophiliacs — because foreign proteins, not HIV, suppress their immune system. 7) Stabilization, even regeneration, of immunity of HIV-positive hemophiliacs by long-term treatment with pure factor VIII. This shows that neither HIV nor factor VIII plus HIV are immunosuppressive by themselves. Therefore, AIDS cannot be prevented by elimination of HIV from the blood supply and cannot be rationally treated with genotoxic antiviral drugs, like AZT. Instead, hemophilia-AIDS can be prevented and has even been reverted by treatment with pure factor VIII.Keywords
This publication has 89 references indexed in Scilit:
- Changes in longevity and causes of death among persons with hemophilia AAmerican Journal of Hematology, 1994
- Quantitation of Human Immunodeficiency Virus in the BloodNew England Journal of Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with HemophiliaNew England Journal of Medicine, 1989
- Functional studies of cell-mediated immunity in haemophilia and other bleeding disordersBritish Journal of Haematology, 1988
- HTLV-III serology in hemophilia: Relationship with immunologic abnormalitiesThe Journal of Pediatrics, 1986
- Hemophiliac immunodeficiency: Influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesvirusesThe Journal of Pediatrics, 1986
- Follow-up at 4½ Years on Homosexual Men with Generalized LymphadenopathyNew England Journal of Medicine, 1985
- HUMAN T-LYMPHOTROPIC VIRUS TYPE III (HTLV-III) INFECTION IN SERONEGATIVE HAEMOPHILIACS AFTER TRANSFUSION OF FACTOR VIIIThe Lancet, 1985
- T-Lymphocyte Subpopulations in Patients with Classic Hemophilia Treated with Cryoprecipitate and Lyophilized ConcentratesNew England Journal of Medicine, 1983